

Onconova Therapeutics Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 19-Feb-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Product Portfolio Summary..... 8

Product Portfolio Financials..... 12

Product Portfolio Drugs..... 13

[Return to Table of Contents](#)

Onconova Therapeutics Inc

COMPANY OVERVIEW

Company Name	Onconova Therapeutics Inc
Parent Company Name	Onconova Therapeutics Inc
Website	http://www.onconova.com/
Country	US
Number of Drugs in Active Development	18
Number of Inactive Drugs	6
Number of Patents as Owner	14
Number of Patents as Third Party	1
Number of Deals	15
Key Indications	Cancer, Hematological neoplasm, Radiation sickness, Solid tumor, Acute myelogenous leukemia, Myelodysplastic syndrome, Acute lymphoblastic leukemia, Central nervous system disease, Chronic myelocytic leukemia, Inflammatory disease, Ovary tumor, Squamous cell carcinoma, Toxicity
Key Target-based Actions	Abl tyrosine kinase inhibitor, Cyclin-dependent kinase-1 inhibitor, Cyclin-dependent kinase inhibitor 1 inhibitor, p53 tumor suppressor protein inhibitor, Bax protein inhibitor, Cyclooxygenase 2 inhibitor, Tumor protein p73 inhibitor, AKT protein kinase inhibitor, BCL2L1 gene stimulator, Bcr protein inhibitor, Casein kinase II inhibitor, Cyclin D1 inhibitor, Jun N terminal kinase modulator, MAP kinase inhibitor, Phosphoinositide 3-kinase inhibitor, Polo-like kinase 1 inhibitor, Tubulin beta inhibitor
Key Technologies	Small molecule therapeutic, Oral formulation, Infusion, Intravenous formulation, Capsule formulation, Prodrug, Subcutaneous formulation, Analytical method, Drug screening, Formulation oral taste-masking, Formulation preservation, Formulation solid oral, Liquid formulation, Quick release

COMPANY PROFILE

SUMMARY

Onconova Therapeutics is a private development-stage biopharmaceutical company founded in 1998, by scientific founder Dr Premkumar Reddy, focused on the development of treatments for cancer and radiation injury.

COMPANY LOCATION

Onconova is located in Newtown, PA and Lawrenceville, NJ.

LICENSING AGREEMENTS

In May 2008, KINAXO Biotechnologies and Onconova Therapeutics agreed to collaborate on the development of novel small molecule therapeutics for cancer treatment and radiation protection.

EARLY R&D

By November 2008, Onconova was investigating a series of immunoconjugate compounds suitable for use with monoclonal antibodies. At that time, the company was seeking to outlicense the program to biopharmaceutical companies.

FINANCIAL

In June 2013, Onconova filed a form S-1 registration statement with the US SEC for the proposed IPO of its common stock. In July 2013, the company announced the pricing of the IPO of 5,166,667 shares of its common stock priced at \$15 each. The underwriters were granted a 30-day option to purchase an additional 7,75,000 shares of the common stock at the same price to cover overallotments. The shares were to begin trading on The NASDAQ Global Market on July 25, 2013 under the ticker symbol 'ONTX'. The offer was expected to close on July 30, 2013. By September 2013,

[Return to Table of Contents](#)




the offering had been closed and the company raised net proceeds of \$79.6 million. In December 2013, NASDAQ reported that, Onconova would be added to the NASDAQ Biotechnology Index under the ticker symbol 'ONTX', as a result of the annual re-ranking, which would become effective prior to market open on December 23, 2013.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	15	6	21
Hematological disease	4	0	4
Endocrine disease	1	1	2
Injury	2	0	2
Gynecology and obstetrics	1	1	2
Dermatological disease	1	0	1
Toxicity and intoxication	1	0	1
Neurological disease	1	0	1
Gastrointestinal disease	0	1	1
Inflammatory disease	1	0	1
Genitourinary disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 2 Clinical	1
Phase 1 Clinical	3
Discovery	10
Suspended	3
No Development Reported	6

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Discovery/Design	0	0	2	0	2
Drug - Funding	2	0	0	0	2
Drug - CRADA	2	0	0	0	2
Drug - Early Research/Development	1	0	5	0	6
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Commercialization License	1	0	0	0	1
Drug - Development Services	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	7	28
Hematological disease	2	5
Endocrine disease	0	3
Genitourinary disease	0	2
Dermatological disease	1	2
Gastrointestinal disease	0	2
Gynecology and obstetrics	0	2
Immune disorder	1	1

[Return to Table of Contents](#)



Trials by Phase

Phase	Ongoing	All
Phase 3	2	3
Phase 2	3	7
Phase 1	3	20
Phase not specified	0	2

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	5	0	5
Endocrine disease	1	0	1
Gastrointestinal disease	3	0	3
Hematological disease	4	0	4
Degeneration	1	0	1
Immune disorder	6	0	6
Musculoskeletal disease	5	0	5
Neoplasm	11	0	11
Genetic disorder	1	0	1
Metabolic disorder	3	0	3
Neurological disease	5	1	6
Infectious disease	2	0	2
Injury	3	0	3
Toxicity and intoxication	1	0	1
Inflammatory disease	7	0	7

[Return to Table of Contents](#)




Gynecology and obstetrics	1	0	1
Dermatological disease	1	0	1
Ulcer	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.


[Return to Table of Contents](#)

PRODUCT PORTFOLIO FINANCIALS

DRUG SALES AND FORECASTS



Drug Sales as a Share of the Total Sales 2015



[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

rigosertib sodium (iv, MDS/solid tumors), Onconova/SymBio

Drug Name	rigosertib sodium (iv, MDS/solid tumors), Onconova/SymBio
Key Synonyms	rigosertib, Novonex, Estybon, rigosertib sodium
Originator Company	Onconova Therapeutics Inc
Active Companies	Baxter International Inc, SymBio Pharmaceuticals Ltd, Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Hematological neoplasm, Myelodysplastic syndrome, Acute myelogenous leukemia, Solid tumor, Pancreas tumor, Acute lymphoblastic leukemia, Ovary tumor
Target-based Actions	Jun N terminal kinase modulator, Polo-like kinase 1 inhibitor, Cyclin-dependent kinase-1 inhibitor, AKT protein kinase inhibitor, Cyclin D1 inhibitor, Phosphoinositide 3-kinase inhibitor, MAP kinase inhibitor, BCL2L11 gene stimulator
Other Actions	Cell cycle inhibitor, Apoptosis stimulator, Anticancer protein kinase inhibitor
Technologies	Intravenous formulation, Infusion, Small molecule therapeutic
Last Change Date	13-Feb-2014

rigosertib sodium (oral capsule, MDS/squamous cell carcinoma/solid tumors), Onconova/SymBio

Drug Name	rigosertib sodium (oral capsule, MDS/squamous cell carcinoma/solid tumors), Onconova/SymBio
Key Synonyms	Estybon, rigosertib sodium, Novonex, rigosertib
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc, SymBio Pharmaceuticals Ltd
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Myelodysplastic syndrome, Solid tumor, Squamous cell carcinoma, Acute myelogenous leukemia, Chronic myelocytic leukemia
Target-based Actions	Jun N terminal kinase modulator, Polo-like kinase 1 inhibitor, Cyclin-dependent kinase-1 inhibitor, AKT protein kinase inhibitor, Phosphoinositide 3-kinase inhibitor, MAP kinase inhibitor, BCL2L11 gene stimulator
Other Actions	Apoptosis stimulator, Anticancer protein kinase inhibitor, Synergist, Cell cycle inhibitor
Technologies	Oral formulation, Capsule formulation, Small molecule therapeutic
Last Change Date	13-Feb-2014

[Return to Table of Contents](#)

recilisib sodium (sc, radiation sickness), Onconova

Drug Name	recilisib sodium (sc, radiation sickness), Onconova
Key Synonyms	Ex-RAD, recilisib sodium, recilisib
Originator Company	Onconova Therapeutics Inc
Active Companies	Pullan Consulting, Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Radiation sickness
Target-based Actions	Cyclin-dependent kinase inhibitor 1 inhibitor, p53 tumor suppressor protein inhibitor, Bax protein inhibitor, Abl tyrosine kinase inhibitor, Tumor protein p73 inhibitor
Other Actions	Anticancer protein kinase inhibitor, Apoptosis inhibitor, Radioprotectant
Technologies	Subcutaneous formulation, Small molecule therapeutic
Last Change Date	24-Jan-2014

briciclib sodium

Drug Name	briciclib sodium
Key Synonyms	briciclib, briciclib sodium
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc, Pullan Consulting
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Hematological neoplasm
Target-based Actions	Cyclin D1 inhibitor
Other Actions	Apoptosis stimulator, Cell cycle inhibitor
Technologies	Prodrug, Intravenous formulation, Infusion, Small molecule therapeutic
Last Change Date	12-Feb-2014

[Return to Table of Contents](#)

recilisib sodium (oral, radiation sickness), Onconova

Drug Name	recilisib sodium (oral, radiation sickness), Onconova
Key Synonyms	Ex-RAD, recilisib, recilisib sodium
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc, Pullan Consulting
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Radiation sickness
Target-based Actions	Cyclin-dependent kinase inhibitor 1 inhibitor, p53 tumor suppressor protein inhibitor, Bax protein inhibitor, Abl tyrosine kinase inhibitor, Tumor protein p73 inhibitor
Other Actions	Anticancer protein kinase inhibitor, Apoptosis inhibitor, Radioprotectant
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	04-Dec-2013

ON-24160

Drug Name	ON-24160
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc, Pullan Consulting
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Tubulin beta inhibitor
Other Actions	Anticancer
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	03-Apr-2013

[Return to Table of Contents](#)

ON-044580

Drug Name	ON-044580
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc, Pullan Consulting
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	IL-3 antagonist, STAT-5 inhibitor, Jak2 tyrosine kinase inhibitor, Abl tyrosine kinase inhibitor, Bcr protein inhibitor
Other Actions	Anticancer protein kinase inhibitor, Apoptosis stimulator
Technologies	Small molecule therapeutic
Last Change Date	20-Sep-2013

ON-123300

Drug Name	ON-123300
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Pullan Consulting, Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	NUAK SNF1-like protein kinase 1 inhibitor, Cyclin-dependent kinase-4 inhibitor
Other Actions	Apoptosis stimulator, Anticancer protein kinase inhibitor
Technologies	Small molecule therapeutic
Last Change Date	19-Sep-2013

[Return to Table of Contents](#)

ON-1231320

Drug Name	ON-1231320
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Polo-like kinase 2 inhibitor, PARP stimulator
Other Actions	Anticancer protein kinase inhibitor
Technologies	Small molecule therapeutic
Last Change Date	08-Jun-2012

mitotic cell cycle inhibitors (cancer), Onconova

Drug Name	mitotic cell cycle inhibitors (cancer), Onconova
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Tubulin alpha inhibitor, Tubulin beta inhibitor
Other Actions	Cell cycle inhibitor
Technologies	Small molecule therapeutic
Last Change Date	09-Nov-2013

[Return to Table of Contents](#)

ALK inhibitors (cancer), Onconova

Drug Name	ALK inhibitors (cancer), Onconova
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Anaplastic lymphoma kinase receptor inhibitor
Other Actions	Anticancer protein kinase inhibitor
Technologies	Small molecule therapeutic
Last Change Date	26-Sep-2012

ON-108600

Drug Name	ON-108600
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Casein kinase II inhibitor, Cyclin-dependent kinase-9 inhibitor
Other Actions	Apoptosis stimulator, Anticancer protein kinase inhibitor, Cell cycle inhibitor
Technologies	Small molecule therapeutic
Last Change Date	01-May-2013

[Return to Table of Contents](#)

ON-146 series (cancer), Onconova

Drug Name	ON-146 series (cancer), Onconova
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Pullan Consulting, Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Hematological neoplasm
Target-based Actions	Phosphoinositide-3 kinase delta inhibitor, Phosphoinositide-3 kinase alpha inhibitor
Other Actions	Anticancer
Technologies	Small molecule therapeutic
Last Change Date	04-Jun-2013

ON-108110

Drug Name	ON-108110
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	PIM-3 protein kinase inhibitor, Casein kinase II inhibitor
Other Actions	Cell cycle inhibitor, Anticancer protein kinase inhibitor, Apoptosis stimulator
Technologies	Small molecule therapeutic
Last Change Date	19-Apr-2013

[Return to Table of Contents](#)

ON-015640

Drug Name	ON-015640
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Tubulin antagonist
Other Actions	Anticancer
Technologies	Small molecule therapeutic
Last Change Date	22-Apr-2013

ON-09300

Drug Name	ON-09300
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Suspended
Active Indications	Cancer
Target-based Actions	Cyclooxygenase 2 inhibitor, 5-Lipoxygenase inhibitor
Other Actions	Anticancer
Technologies	Small molecule therapeutic
Last Change Date	14-Nov-2008

[Return to Table of Contents](#)

ON-09250

Drug Name	ON-09250
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Suspended
Active Indications	Central nervous system disease, Inflammatory disease
Target-based Actions	Cyclooxygenase 2 inhibitor
Other Actions	Anti-inflammatory
Technologies	Small molecule therapeutic
Last Change Date	09-Aug-2004

ON-01500 series, Onconova

Drug Name	ON-01500 series, Onconova
Key Synonyms	
Originator Company	Onconova Therapeutics Inc
Active Companies	Onconova Therapeutics Inc
Inactive Companies	
Highest Status	Suspended
Active Indications	Toxicity, Cancer
Target-based Actions	Cyclin-dependent kinase-1 inhibitor
Other Actions	Cell cycle inhibitor, Anticancer protein kinase inhibitor, Anticancer, Chemoprotectant, Angiogenesis inhibitor
Technologies	Small molecule therapeutic
Last Change Date	02-Jun-2010

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

